The Latest Breaking News from Merck

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

With advancements in biomedical sciences and promising drug pipelines, the healthcare industry is set for substantial growth in the coming years. Hence, investors might find opportunities in adding UnitedHealth Group (UNH), Merck & Co. (MRK), and Pfizer (PFE) to their portfolios for potential gains this year. Read on….

Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday.

Merck stock has been struggling since the July 30 earnings announcement and could provide a nice bearish candidate.

These defensive healthcare picks from the Dow Jones Industrial Average are worth a look at current levels for investors seeking passive income.

Despite Merck & Co.’s relative underperformance over the past year, Wall Street analysts remain bullish about the stock’s prospects.

The stock market took a bearish turn amid economic fears. Apple and Meta had strong results, while AI spending remains robust.

Stocks fell Tuesday as the Fed meeting got underway. Microsoft fell ahead of earnings while Merck and Proctor & Gamble plunged after results.